PAOG Targets $18 Billion Market Opportunity With New CBD Nutraceutical To Be Packaged By ALKM And Marketed By USMJ

Rhea-AI Summary

PAO Group, Inc. (OTC Pink: PAOG) announced a CBD Nutraceuticals Business Development Update on June 24, 2021. The company aims to generate revenue from CBD Nutraceuticals this year, alongside its pharmaceutical projects. The CBD line includes products targeting anxiety and COPD, with anticipated market values reaching $18 billion and $16.4 billion respectively by 2025 and 2027. A new PhD in Pharmacological Sciences has joined the team to lead this initiative. PAOG plans collaboration with Alkame Holdings for production and North American Cannabis Holdings for distribution.

Positive

• PAOG expects to generate revenue this year from CBD Nutraceuticals.
• The CBD Nutraceutical market is projected to grow from $5.2 billion in 2020 to $16.4 billion by 2027.
• The first product, CBD RELAX-RX, targets the anxiety and depression market, expected to reach a value of $18 billion by 2025.
• Partnership with Alkame Holdings for product development and North American Cannabis Holdings for distribution will enhance market reach.

Negative

• Potential technical complications could hinder product launch timelines.
• The company has not yet generated any revenue from its CBD initiatives as of the announcement date.

Sandusky, Ohio, June 24, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today published a CBD Nutraceuticals Business Development Update. PAOG expects to generate revenue this year from its CBD Nutraceuticals.

PAOG’s CBD Nutraceuticals Business Development initiative is a complimentary effort running in parallel to PAOG’s ongoing Pharmaceutical Developments. 

PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."

PAOG is drawing on its CBD Pharmaceutical Intellectual Property in the development of its CBD Nutraceuticals.

PAOG plans to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. 

The 2020 CBD Nutraceuticals Market had an estimated value of $5.2 Billion and it is expected to reach $16.4 Billion by 2027.

The first CBD Nutraceutical under development will sell under the name CBD RELAX-RX targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025.

The second CBD Nutraceutical under development will be derived from PAOG's ongoing COPD research targeting the COPD treatment market separately from the pharmaceutical market also targeting COPD treatment.

The third CBD Nutraceutical is being developed in partnership with the EVERx CBD Sports Water Brand owned by Puration, Inc. (OTC Pink: PURA) and will target the sports nutrition market.

PAOG has recently brought a new PhD in Pharmacological Sciences on board to lead the CBD Nutraceuticals and Pharmaceuticals Team.  Look for a detail announcement coming soon.

PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor.

Learn more about PAOG at www.paogroupinc.com.

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFORMATION

Contact Us:
Jim DiPrima
888-272-6472
info@pao.group

FAQ

What are PAOG's plans for CBD Nutraceuticals in 2021?

PAOG plans to generate revenue from its CBD Nutraceuticals line in 2021, launching multiple products targeting anxiety, COPD, and sports nutrition.

What is the expected market value of the CBD Nutraceuticals by 2027?

The CBD Nutraceuticals market is projected to grow from $5.2 billion in 2020 to $16.4 billion by 2027.

Which companies is PAOG partnering with for CBD Nutraceuticals?

PAOG is partnering with Alkame Holdings for co-packing and North American Cannabis Holdings for distribution.

What is the target market for the CBD RELAX-RX product?

CBD RELAX-RX is targeting the anxiety and depression treatment market, which is expected to reach $18 billion by 2025.

What new hire has PAOG made to lead its CBD initiatives?

PAOG has recently brought on a new PhD in Pharmacological Sciences to lead the CBD Nutraceuticals and Pharmaceuticals Team.